바이젠셀

308080KOSDAQSector: Pharma & Biotech

₩5,070▼ 1.55%Market cap ₩103.9BAs of Jul 21, 2026 close · updated once daily

Grade D39.2 ptsTop 72% of 2,523 stocks

Financial strength

48.5

Price attractiveness

28.5

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

ⓘ Growth momentum not rated — will be included automatically as data accumulates

Financial strength

48.5

How much debt does it carry relative to equity?

Debt-to-equity ratio

24.1%

✓ Above median · Top 23.8% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

2003.5%

✓ Above median · Top 4.3% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

-75453.1%

✗ Below median · Top 99% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

-37.3%

✗ Below median · Top 79.1% in sector

Sector median -4.5%

Source filing: annual report (separate) — view original ↗

Price attractiveness

28.5

Is the price expensive relative to earnings?

P/E (price-to-earnings)

Loss-making (P/E not computable)

✗ Below median · Top 79.1% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

2.38x

✗ Below median · Top 64% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15